Commitments Made Are Decisive Step to Create in Morocco Biopharmaceutical Pole of Excellence in Africa (Samsung Biologics Vice-Pres.)
"The commitments we are making today are a decisive step that will create in Morocco of a biopharmaceutical pole of excellence on the Continent, which we want to be recognized globally," said Machour on the occasion of the launch and signing of agreements relating to the project to fill-finish manufacturing of anti-Covid19 vaccine and other vaccines in Morocco.
Machour, who presented before HM the King the implementation plan of the Royal Vision to establish in the Kingdom, a continental champion in the next five years in the fields of research, development, production and marketing of vaccines and biotherapies with high added value, stressed that these capabilities will serve Morocco, the African continent and the world.
The Royal vision should ensure a health autonomy of Morocco and create the necessary conditions to pull up the capacities of Africa in the production of vaccines and critical therapies, he said, noting that this vision is based on three important steps, the first of which is an emergency phase, which will start immediately.
This step, said Machour, will allow Morocco to use the filling capacity in vials or pre-filled syringes already existing in the country, specifying that this phase is more specifically to initiate a technical cooperation between Sinopharm and the company Sothema.
He noted that this cooperation will be established under the supervision and in partnership with the ministry of Health, the ministry of Foreign Affairs and all ministries already involved.
The second phase, which will start in parallel with the first, is to create in partnership with the company Recipharm, the fifth largest drug manufacturer in the world, a production site for vaccines and biotherapies with a quality level and regulatory standards recognized worldwide, he noted.
As for the third step, it provides for creating the necessary context so that Morocco can be part of the great of this world, recognized as a serious and credible platform for development and production of vaccines and biotherapies, he added.
The Very High solicitude and the Royal benevolence are factors of success essential to the achievement of this Vision, he said, noting that the already existing public-private partnership will allow to mobilize all actors in Morocco and elsewhere around the same objective.
A strategic alliance with a world leader in the manufacture of vaccines and biotherapies is also a key element to accelerate the transfer of knowledge and technology and position the Kingdom at continental and global levels, he concluded.
Machour, who presented before HM the King the implementation plan of the Royal Vision to establish in the Kingdom, a continental champion in the next five years in the fields of research, development, production and marketing of vaccines and biotherapies with high added value, stressed that these capabilities will serve Morocco, the African continent and the world.
The Royal vision should ensure a health autonomy of Morocco and create the necessary conditions to pull up the capacities of Africa in the production of vaccines and critical therapies, he said, noting that this vision is based on three important steps, the first of which is an emergency phase, which will start immediately.
This step, said Machour, will allow Morocco to use the filling capacity in vials or pre-filled syringes already existing in the country, specifying that this phase is more specifically to initiate a technical cooperation between Sinopharm and the company Sothema.
He noted that this cooperation will be established under the supervision and in partnership with the ministry of Health, the ministry of Foreign Affairs and all ministries already involved.
The second phase, which will start in parallel with the first, is to create in partnership with the company Recipharm, the fifth largest drug manufacturer in the world, a production site for vaccines and biotherapies with a quality level and regulatory standards recognized worldwide, he noted.
As for the third step, it provides for creating the necessary context so that Morocco can be part of the great of this world, recognized as a serious and credible platform for development and production of vaccines and biotherapies, he added.
The Very High solicitude and the Royal benevolence are factors of success essential to the achievement of this Vision, he said, noting that the already existing public-private partnership will allow to mobilize all actors in Morocco and elsewhere around the same objective.
A strategic alliance with a world leader in the manufacture of vaccines and biotherapies is also a key element to accelerate the transfer of knowledge and technology and position the Kingdom at continental and global levels, he concluded.